424 related articles for article (PubMed ID: 15073846)
1. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
2. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
3. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
[TBL] [Abstract][Full Text] [Related]
5. Loss expression of active fragile sites genes associated with the severity of breast epithelial abnormalities.
Wang TT; Frezza EE; Ma R; Hu SY; Liu CZ; Zhang GY; Wachtel MS; Lü XM; Feng JB; Lü CX
Chin Med J (Engl); 2008 Oct; 121(20):1969-74. PubMed ID: 19080258
[TBL] [Abstract][Full Text] [Related]
6. Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.
Dincer N; Tezel GG; Sungur A; Himmetoglu C; Huebner K; Güler G
Oral Oncol; 2010 Mar; 46(3):195-9. PubMed ID: 20060354
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
8. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
9. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
11. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
12. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors.
Driouch K; Prydz H; Monese R; Johansen H; Lidereau R; Frengen E
Oncogene; 2002 Mar; 21(12):1832-40. PubMed ID: 11896615
[TBL] [Abstract][Full Text] [Related]
13. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.
Płuciennik E; Kusińska R; Potemski P; Kubiak R; Kordek R; Bednarek AK
Eur J Surg Oncol; 2006 Mar; 32(2):153-7. PubMed ID: 16360296
[TBL] [Abstract][Full Text] [Related]
14. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.
Bednarek AK; Keck-Waggoner CL; Daniel RL; Laflin KJ; Bergsagel PL; Kiguchi K; Brenner AJ; Aldaz CM
Cancer Res; 2001 Nov; 61(22):8068-73. PubMed ID: 11719429
[TBL] [Abstract][Full Text] [Related]
15. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
16. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.
Capuzzi D; Santoro E; Hauck WW; Kovatich AJ; Rosato FE; Baffa R; Huebner K; McCue PA
Cancer; 2000 Jan; 88(1):24-34. PubMed ID: 10618602
[TBL] [Abstract][Full Text] [Related]
17. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
[TBL] [Abstract][Full Text] [Related]
18. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
19. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
20. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.
Campiglio M; Pekarsky Y; Menard S; Tagliabue E; Pilotti S; Croce CM
Cancer Res; 1999 Aug; 59(16):3866-9. PubMed ID: 10463571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
